logo

For the Inventor, By the Inventor

Utrecht, Netherlands

Merus N.v.


USPTO Granted Patents = 48

% Expired Patents = 6.3



Trademarks = 10

Forward Citations = 135

Loading Chart...
Loading Chart...

35 inventors (with patents filed for the assignee):

goldMedal Ton Logtenberg (38 out of 59 patents)

silverMedal Mark Throsby (24 out of 50 patents)

bronzeMedal Cornelis Adriaan De Kruif (23 out of 54 patents)

4.  Cecilia Anna Wilhelmina Geuijen (10 out of 15 patents)

5.  Rui Daniel Pinto (9 out of 9 patents)

6.  Erwin Houtzager (9 out of 12 patents)

7.  Alexander Berthold Hendrik Bakker (9 out of 17 patents)

8.  Pieter Fokko Van Loo (8 out of 11 patents)

9.  Linda Johanna Aleida Hendriks (7 out of 10 patents)

10.  Robert Arjen Kramer (7 out of 15 patents)

11.  Rinse Klooster (6 out of 10 patents)

12.  Paulus Johannes Tacken (5 out of 6 patents)

13.  John De Kruif (3 out of 3 patents)

14.  Robertus Cornelis Roovers (3 out of 6 patents)

15.  Ronald Hendrik Brus (2 out of 3 patents)


Core Competencies:
Binding Molecules
Bispecific Antibodies
CD137
PD-L1
EGFR
TGF-Beta-RII
ErbB-2
ErbB-3
Cancer Growth Inhibition
T Cell Engagers
Antibody Production
Immunomodulation

48 patents:

1. 12723095 - METHODS OF TREATING CANCER USING BINDING MOLECULES THAT BIND CD137 AND PD-L1 (2026-09-01),
2. 12668638 - ANTIBODIES THAT BIND EGFR AND CMET (2026-06-30),
3. 12577327 - MIXED BINDING DOMAINS (2026-03-17),
4. 12577306 - BISPECIFIC ANTI PD1-ANTI TIM3 ANTIBODIES (2026-03-17),
5. 12570747 - TGF-BETA-RII BINDING PROTEINS (2026-03-10),
6. 12503509 - CLEC12AXCD3 BISPECIFIC ANTIBODIES AND METHODS FOR THE TREATMENT OF DISEASE (2025-12-23),
7. 12460002 - CD3 binding molecules (2025-11-04),
8. 12291798 - Generation of binding molecules (2025-05-06),
9. 12247078 - ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene (2025-03-11),
10. 12195551 - Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer (2025-01-14),
11. 12139548 - Antibody that binds ErbB-2 and ErbB-3 (2024-11-12),
12. 12123043 - Methods and means for the production of Ig-like molecules (2024-10-22),
13. 12060418 - Bispecific IgG antibodies as T cell engagers (2024-08-13),
14. 11993654 - PD-1 binding domains (2024-05-28),
15. 11952424 - Multivalent antibody (2024-04-09),
Company Overview
Merus N.V. is a biotechnology company based in Utrecht, Netherlands, specializing in the development of innovative therapeutic solutions for cancer treatment. The company focuses on creating bispecific antibodies and CD3 binding molecules that engage T cells to target and eliminate cancer cells. With a strong emphasis on ErbB-2 and ErbB-3 antibodies, Merus is dedicated to advancing its proprietary technology platforms to enhance the efficacy of immunotherapies, aiming to improve patient outcomes in oncology.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Merus N.v. USPTO Patent Assignee Logo
48 Patents

#5 in Utrecht

#175 in Netherlands

#14,550 in the World

Utrecht, NL
Utrecht, Netherlands

Merus N.v.

Forward Citations = 135

35 inventors:

goldMedal Ton Logtenberg (38 out of 59 patents)

silverMedal Mark Throsby (24 out of 50 patents)

bronzeMedal Cornelis Adriaan De Kruif (23 out of 54 patents)

4.  Cecilia Anna Wilhelmina Geuijen (10 out of 15 patents)

5.  Rui Daniel Pinto (9 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Merus N.v.. Retrieved from https://idiyas.com/company/merus-n-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…